CNS prophylaxis for diffuse large B-cell lymphoma

Toby A. Eyre; Kerry J. Savage; Chan Y. Cheah; Tarec C. El-Galaly; Katharine L. Lewis; Pamela McKay; Matthew R. Wilson; Andrew M. Evens; Sabela Bobillo; Diego Villa; Matthew J. Maurer; Kate Cwynarski; Andrés J.M. Ferreri

doi:10.1016/S1470-2045(22)00371-0

CNS prophylaxis for diffuse large B-cell lymphoma

Toby A. Eyre, Kerry J. Savage, Chan Y. Cheah, Tarec C. El-Galaly, Katharine L. Lewis, Pamela McKay, Matthew R. Wilson, Andrew M. Evens, Sabela Bobillo, Diego Villa, Matthew J. Maurer, Kate Cwynarski, Andrés J.M. Ferreri

Quantitative Health Sciences

Research output: Contribution to journal › Review article › peer-review

Abstract

CNS relapse in the brain parenchyma, eyes, or leptomeninges is an uncommon but devastating complication of diffuse large B-cell lymphoma. CNS prophylaxis strategies, typically involving intrathecal or high-dose antimetabolites, have been developed in the front-line treatment setting with the aim to reduce this subsequent risk. Clinical and biological features associated with elevated risk are increasingly well defined and are discussed in this Review. This Review summarises both the historical and current developments in this challenging field, provides a nuanced discussion regarding current reasons for and against standard prophylactic measures, outlines evidence for the timing of prophylactic measures when delivered, and reflects on possible future developments.

Original language	English (US)
Pages (from-to)	e416-e426
Journal	The Lancet Oncology
Volume	23
Issue number	9
DOIs	https://doi.org/10.1016/S1470-2045(22)00371-0
State	Published - Sep 2022

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(22)00371-0

Cite this

@article{9fbed729cfde4048b0bd76412882a899,

title = "CNS prophylaxis for diffuse large B-cell lymphoma",

abstract = "CNS relapse in the brain parenchyma, eyes, or leptomeninges is an uncommon but devastating complication of diffuse large B-cell lymphoma. CNS prophylaxis strategies, typically involving intrathecal or high-dose antimetabolites, have been developed in the front-line treatment setting with the aim to reduce this subsequent risk. Clinical and biological features associated with elevated risk are increasingly well defined and are discussed in this Review. This Review summarises both the historical and current developments in this challenging field, provides a nuanced discussion regarding current reasons for and against standard prophylactic measures, outlines evidence for the timing of prophylactic measures when delivered, and reflects on possible future developments.",

author = "Eyre, {Toby A.} and Savage, {Kerry J.} and Cheah, {Chan Y.} and El-Galaly, {Tarec C.} and Lewis, {Katharine L.} and Pamela McKay and Wilson, {Matthew R.} and Evens, {Andrew M.} and Sabela Bobillo and Diego Villa and Maurer, {Matthew J.} and Kate Cwynarski and Ferreri, {Andr{\'e}s J.M.}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = sep,

doi = "10.1016/S1470-2045(22)00371-0",

language = "English (US)",

volume = "23",

pages = "e416--e426",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "9",

}

TY - JOUR

T1 - CNS prophylaxis for diffuse large B-cell lymphoma

AU - Eyre, Toby A.

AU - Savage, Kerry J.

AU - Cheah, Chan Y.

AU - El-Galaly, Tarec C.

AU - Lewis, Katharine L.

AU - McKay, Pamela

AU - Wilson, Matthew R.

AU - Evens, Andrew M.

AU - Bobillo, Sabela

AU - Villa, Diego

AU - Maurer, Matthew J.

AU - Cwynarski, Kate

AU - Ferreri, Andrés J.M.

PY - 2022/9

Y1 - 2022/9

N2 - CNS relapse in the brain parenchyma, eyes, or leptomeninges is an uncommon but devastating complication of diffuse large B-cell lymphoma. CNS prophylaxis strategies, typically involving intrathecal or high-dose antimetabolites, have been developed in the front-line treatment setting with the aim to reduce this subsequent risk. Clinical and biological features associated with elevated risk are increasingly well defined and are discussed in this Review. This Review summarises both the historical and current developments in this challenging field, provides a nuanced discussion regarding current reasons for and against standard prophylactic measures, outlines evidence for the timing of prophylactic measures when delivered, and reflects on possible future developments.

AB - CNS relapse in the brain parenchyma, eyes, or leptomeninges is an uncommon but devastating complication of diffuse large B-cell lymphoma. CNS prophylaxis strategies, typically involving intrathecal or high-dose antimetabolites, have been developed in the front-line treatment setting with the aim to reduce this subsequent risk. Clinical and biological features associated with elevated risk are increasingly well defined and are discussed in this Review. This Review summarises both the historical and current developments in this challenging field, provides a nuanced discussion regarding current reasons for and against standard prophylactic measures, outlines evidence for the timing of prophylactic measures when delivered, and reflects on possible future developments.

UR - http://www.scopus.com/inward/record.url?scp=85137120902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85137120902&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(22)00371-0

DO - 10.1016/S1470-2045(22)00371-0

M3 - Review article

C2 - 36055310

AN - SCOPUS:85137120902

SN - 1470-2045

VL - 23

SP - e416-e426

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 9

ER -

CNS prophylaxis for diffuse large B-cell lymphoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this